Other adverse events occurring in over 5% of patients included anemia (51.5%), ALT/AST elevation (47%), thrombocytopenia (39.4%), renal damage (36.4%), increased blood bilirubin (31.8%), fatigue (31.8%), myelosuppression (30.0%), hypoalbuminemia (27.3%), hypothyroidism (27.3%), decreased appetite (21.2%), proteinuria (18.2%), and abdominal pain (9.1%). This evidence concerns the gene GPT and Thrombocytopenia.